Edgewise Therapeutics, Inc. EWTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $42.65M+16.0% | $43.59M+19.9% | $37.48M+16.3% | $33.56M+9.4% | $36.76M+32.7% | ||
| $11.46M+24.6% | $12.39M+35.1% | $9.38M+14.2% | $9.05M+21.9% | $9.2M+30.4% | ||
| $54.12M+17.7% | $55.98M+22.9% | $46.86M+15.9% | $42.61M+11.8% | $45.96M+32.2% | ||
| -$54.12M-17.7% | -$55.98M-22.9% | -$46.86M-15.9% | -$42.61M-11.8% | -$45.96M-32.2% | ||
| -$49.01M-20.1% | -$50.22M-26.6% | -$40.67M-19.2% | -$36.12M-14.7% | -$40.8M-43.0% | ||
| -$0.46-7.0% | -$0.48-14.3% | -$0.39-8.3% | -$0.340.0% | -$0.43-30.3% | ||
| -$53.58M-17.9% | -$55.45M-23.3% | -$46.36M-16.1% | -$42.11M-12.0% | -$45.45M-32.6% | ||
| -$54.12M-17.7% | -$55.98M-22.9% | -$46.86M-15.9% | -$42.61M-11.8% | -$45.96M-32.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Edgewise Therapeutics, Inc. profitable?
- Edgewise Therapeutics, Inc. is not currently profitable: it reported a net loss of $176.0M over the trailing twelve months.
- What is Edgewise Therapeutics, Inc.'s earnings per share?
- Edgewise Therapeutics, Inc.'s diluted EPS over the trailing twelve months is $-1.67.
- Where does Edgewise Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Edgewise Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.